[go: up one dir, main page]

BR112017021669A2 - formulações farmacêuticas orais, método para tratar doenças e uso de ditas formulações - Google Patents

formulações farmacêuticas orais, método para tratar doenças e uso de ditas formulações

Info

Publication number
BR112017021669A2
BR112017021669A2 BR112017021669A BR112017021669A BR112017021669A2 BR 112017021669 A2 BR112017021669 A2 BR 112017021669A2 BR 112017021669 A BR112017021669 A BR 112017021669A BR 112017021669 A BR112017021669 A BR 112017021669A BR 112017021669 A2 BR112017021669 A2 BR 112017021669A2
Authority
BR
Brazil
Prior art keywords
formulations
crystals
treating diseases
oral pharmaceutical
pharmaceutical formulations
Prior art date
Application number
BR112017021669A
Other languages
English (en)
Inventor
Kesarwani Amit
Chaudhari Anita
Mathur Anoop
Dutt Chaitanya
Abraham Jaya
Kotecha Jignesh
Patel Manish
Chandra Gupta Ramesh
Latad Sachin
Deshpande Shailesh
Kumar Zambad Shital
Mishra Vivek
Original Assignee
Torrent Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Torrent Pharmaceuticals Ltd filed Critical Torrent Pharmaceuticals Ltd
Publication of BR112017021669A2 publication Critical patent/BR112017021669A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4436—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/541—Organic ions forming an ion pair complex with the pharmacologically or therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

esta invenção refere-se a formulações farmacêuticas compreendendo 1-(2-tieno-2'-ila-2-oxo-etila)-3-(metanossulfonil hidrazina carbonila)piridínio, seus sais farmaceuticamente aceitáveis, co-cristais de sal e co-cristais, particularmente cloreto de 1-(2-tieno-2'-ila-2-oxo-etila)-3-(metanossulfonil hidrazina carbonila)piridínio. as formulações são adequadas para administração oral, e também compreendem um melhorador de permeabilidade ou uma base adequada, ou uma mistura destes. as formulações desta invenção servem para o tratamento de doenças associadas com produtos finais de glicação avançada.
BR112017021669A 2015-04-08 2016-04-05 formulações farmacêuticas orais, método para tratar doenças e uso de ditas formulações BR112017021669A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN1475MU2015 2015-04-08
PCT/IB2016/051920 WO2016162787A1 (en) 2015-04-08 2016-04-05 Pharmaceutical formulations

Publications (1)

Publication Number Publication Date
BR112017021669A2 true BR112017021669A2 (pt) 2018-07-10

Family

ID=55808800

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112017021669A BR112017021669A2 (pt) 2015-04-08 2016-04-05 formulações farmacêuticas orais, método para tratar doenças e uso de ditas formulações

Country Status (31)

Country Link
US (1) US10772879B2 (pt)
EP (1) EP3280447B1 (pt)
JP (1) JP6736656B2 (pt)
KR (1) KR20170134662A (pt)
CN (1) CN107530287B (pt)
AR (1) AR104185A1 (pt)
AU (1) AU2016246124B2 (pt)
BR (1) BR112017021669A2 (pt)
CA (1) CA2997463A1 (pt)
CY (1) CY1121921T1 (pt)
DK (1) DK3280447T3 (pt)
EA (1) EA037041B1 (pt)
ES (1) ES2724629T3 (pt)
HR (1) HRP20190783T1 (pt)
HU (1) HUE044889T2 (pt)
IL (1) IL254794B (pt)
LT (1) LT3280447T (pt)
MX (1) MX387639B (pt)
MY (1) MY182008A (pt)
PH (1) PH12017501829A1 (pt)
PL (1) PL3280447T3 (pt)
PT (1) PT3280447T (pt)
RS (1) RS58708B1 (pt)
SG (1) SG11201708142XA (pt)
SI (1) SI3280447T1 (pt)
SM (1) SMT201900264T1 (pt)
TR (1) TR201906476T4 (pt)
TW (1) TWI713512B (pt)
UA (1) UA123051C2 (pt)
WO (1) WO2016162787A1 (pt)
ZA (1) ZA201707094B (pt)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014007972A2 (en) 2012-06-15 2014-01-09 Nova Southeastern University Epinephrine nanoparticles, methods of fabrication thereof, and methods for use thereof for treatment of conditions responsive to epinphrine
PL2976072T3 (pl) 2013-03-22 2021-11-22 Nova Southeastern University Drobne cząstki epinefryny i sposoby ich stosowania do leczenia chorób reagujących na epinefrynę
KR20210080429A (ko) * 2018-10-19 2021-06-30 노바 사우쓰이스턴 유니버시티 피에이치 조절 부형제 및 침투 향상제를 포함하는 설하 에피네프린 조성물 및 그의 사용 방법
MX2021012033A (es) 2019-04-03 2021-11-03 Astellas Pharma Inc Composicion farmaceutica.
KR102330597B1 (ko) * 2020-04-17 2021-11-26 보령제약 주식회사 무정형의 엠파글리플로진을 포함하는 안정성이 향상된 신규 약제학적 제형

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002537321A (ja) * 1999-02-22 2002-11-05 エラン コーポレイション ピーエルスィー 促進剤を含む固体経口剤形
DE69915143T2 (de) * 1999-10-06 2004-10-14 Torrent Pharmaceuticals Ltd., Ahmedabad Pyridinium-derivate zur behandlung von altersbedingten und diabetischen vaskulären komplikationen, verfahren zu ihrer herstellung und ihre pharmazeutischen anwendungen
EP1243581B1 (en) 2001-03-21 2005-07-13 Torrent Pharmaceuticals Ltd Pyridinium compounds useful for the treatment of AGE-related diseases
JP2009529005A (ja) 2006-03-03 2009-08-13 トレント・ファーマシューティカルズ・リミテッド アンジオテンシン１受容体（ａｔ１）とエンドセリンａ（ｅｔａ）受容体に対する新規な二重作用受容体拮抗薬（ｄａｒａ）
JP2009023932A (ja) * 2007-07-18 2009-02-05 Tama Tlo Kk Ｎ−メチルピリジニウム化合物を有効成分として含有する抗ウイルス剤、それを含有する、抗ウイルス組成物、食餌及び動物用飼料
RU2010135524A (ru) * 2008-01-25 2012-02-27 Торрент Фармасьютикалз Лтд. (In) Фармацевтические комбинации
CN101574343B (zh) * 2008-05-07 2011-06-01 吉林大学 一种治疗糖尿病的药物组合物
EP2427432A2 (en) * 2009-05-07 2012-03-14 Torrent Pharmaceuticals Limited Novel heterocyclic compounds
AU2010339907A1 (en) * 2009-12-16 2012-07-05 Nod Pharmaceuticals, Inc. Compositions and methods for oral drug delivery
CN104069066B (zh) * 2013-03-25 2017-04-19 吉林大学 黄癸固体分散体及其在治疗糖尿病及并发症中的应用

Also Published As

Publication number Publication date
TR201906476T4 (tr) 2019-05-21
CY1121921T1 (el) 2020-10-14
HUE044889T2 (hu) 2019-11-28
AU2016246124B2 (en) 2019-11-14
LT3280447T (lt) 2019-05-27
SMT201900264T1 (it) 2019-07-11
MX2017012942A (es) 2018-01-30
EA201792237A1 (ru) 2018-02-28
HRP20190783T1 (hr) 2019-06-28
WO2016162787A1 (en) 2016-10-13
IL254794A0 (en) 2017-12-31
MY182008A (en) 2021-01-18
CN107530287B (zh) 2020-11-10
JP2018510916A (ja) 2018-04-19
AU2016246124A1 (en) 2017-11-02
PH12017501829A1 (en) 2018-04-23
DK3280447T3 (da) 2019-05-13
MX387639B (es) 2025-03-18
IL254794B (en) 2021-05-31
ES2724629T3 (es) 2019-09-12
US20180110763A1 (en) 2018-04-26
ZA201707094B (en) 2021-04-28
US10772879B2 (en) 2020-09-15
EP3280447A1 (en) 2018-02-14
CN107530287A (zh) 2018-01-02
UA123051C2 (uk) 2021-02-10
JP6736656B2 (ja) 2020-08-05
RS58708B1 (sr) 2019-06-28
PL3280447T3 (pl) 2019-07-31
TW201642858A (zh) 2016-12-16
TWI713512B (zh) 2020-12-21
SG11201708142XA (en) 2017-11-29
KR20170134662A (ko) 2017-12-06
AR104185A1 (es) 2017-07-05
EA037041B1 (ru) 2021-01-29
SI3280447T1 (sl) 2019-06-28
CA2997463A1 (en) 2016-10-13
EP3280447B1 (en) 2019-02-27
PT3280447T (pt) 2019-05-14

Similar Documents

Publication Publication Date Title
CY1124432T1 (el) Φαρμακευτικες συνθεσεις που αποτελουν ν-(3,5-διμεθοδυφαινυλ)-ν'-(1-μεθυλαιθυλ)-ν-[3-(1--μεθυλ-1η-πυραζολ-4-υλ)κινοοξαλιν-6-υλ]αιθανο-1,2-διαμινη
CY1122566T1 (el) Παραγωγο 6,7,8,9-tetpaϋδpo-3h-πυραζολo[4,3-f] ισοκινολινης χρησιμο στη θεραπευτικη αντιμετωπιση του καρκινου
PH12021550992A1 (en) Compounds, pharmaceutical compositions, and methods of preparing compounds and of their use as atr kinase inhibitors
JOP20190229A1 (ar) مركبات تثبط بروتين mcl-1
JOP20200001A1 (ar) كاربوكسأميدات بوصفها معدلات لقنوات الصوديوم
SA518400356B1 (ar) مثبطات الأرجيناز واستخداماتها العلاجية
MX2021004639A (es) Combinaciones de inhibidores de desmetilasa-1 especifica de lisina (lsd1) para uso en el tratamiento de tumores solidos.
PH12017500367B1 (en) Compounds that inhibit mcl-1 protein
UA122346C2 (uk) ТЕТРАГІДРО-1H-ПІРИДО[3,4-b]ІНДОЛЬНІ АНТИЕСТРОГЕННІ ЛІКАРСЬКІ ПРЕПАРАТИ
MX373042B (es) Moleculas para administracion a celulas cancerosas mutantes ros1.
MY187047A (en) Selective pyy compounds and uses thereof
BR112017003054A2 (pt) compostos de aminopirimidinila como inibidores de jak
BR112017021669A2 (pt) formulações farmacêuticas orais, método para tratar doenças e uso de ditas formulações
EA201891267A1 (ru) Фармацевтическая композиция, содержащая действенный ингибитор urat1
JOP20190053A1 (ar) مركبات أزا إندازول للاستخدام في إصابات الأوتار و/ أو الرباط
BR112018070536A2 (pt) composto, composição farmacêutica, combinação, uso de um composto ou um sal farmaceuticamente aceitável do mesmo, e, método de tratamento de uma doença ou condição
EA201891319A1 (ru) Соединения алкилдигидрохинолинсульфонамида
JOP20190049A1 (ar) مثبطات دوبامين-b-هيدروكسيلاز
MX389336B (es) Formulacion farmaceutica.
EA201692298A1 (ru) Производные карбоксамидов
EP4477265A3 (en) Methods of treating new-onset plaque type psoriasis using il-17 antagonists
MX379253B (es) Formulaciones de oximetazolina estabilizadas y sus usos.
BR112019000897A2 (pt) sal de adição de ácido, composição farmacêutica, uso do sal de adição de ácido ou da composição farmacêutica, e, método para prevenção, tratamento ou atenuação de um distúrbio de fibrose de tecido ou órgão.
BR112018070514A2 (pt) composto, composição farmacêutica, combinação, uso de um composto ou um sal farmaceuticamente aceitável do mesmo, e, método de tratamento de uma doença ou condição
JOP20190054A1 (ar) مركبات إندازول للاستخدام في إصابات الأوتار و/ أو الرباط

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements